marked.bio

anti-PD-L1 antibody · antibody

benmelstobart

3 active trials across 5 of our biomarkers, targeting PD-L1. Not approved for any biomarker on marked.bio yet.

Also known as TQB2450.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
Claudin 18.2 expression 1 2 Phase 2
KRAS G12C 1 1 Phase 2
MSI-H / dMMR 1 1 Phase 2
ALK fusion 0 1 –
EGFR exon 19 deletion / L858R 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of benmelstobart.

  1. LaNova Medicines Zhejiang 1

Trials

3 of 5 trials shown

  1. Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

    Not yet recruiting Phase 2 Sun Yat-sen University Started 2025Primary completion 2028-10 NCT07294261

    garsorasibbenmelstobartanlotinibcetuximab

    Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

    KRAS G12CLocal Advanced or Metastatic NSCLC

  2. TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

    Recruiting Phase 2 Fudan University Started 2025Primary completion 2027-10 NCT06914297

    benmelstobart

    EC molecular typing, resulting in MMRd type (molecular typing is based on the World Health Organization (WHO) classification cri…

    MSI-H / dMMREndometrial Cancer

  3. A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

    Recruiting Phase 2 LaNova Medicines Zhejiang Started 2023Primary completion 2031-08 NCT05934331

    LM-302toripalimabcapecitabineTegafur, Gimeracil and Oteracil Potassium Capsulesnivolumabapatinibgemcitabinetislelizumabanlotinibbenmelstobart

    CLDN18.2-positive subjects.

    Claudin 18.2 expressionMalignant Neoplasms of Digestive Organs